The Food and Drug Administration on Wednesday approved an injectable drug in the treatment of a rare group of bone marrow diseases that are often fatal.
The FDA said Dacogen would give another treatment option to people suffering from myelodysplastic syndromes, a condition in which bone marrow does not produce an adequate amount of mature blood cells
